This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Diagnostic criteria for MGUS (Monoclonal Gammopathy of Unknown Significance), asymptomatic myeloma and symptomatic myeloma

Authoring team

The diagnosis of myeloma should be made using the criteria proposed by the International Myeloma Working Group (IMWG). These criteria distinguish between myeloma and MGUS principally on the basis of M protein concentration, percentage of bone marrow plasma cells and the presence or absence of myeloma related organ and tissue impairment (1).

  • MGUS
    • M-protein in serum <30 g/l
    • Bone marrow clonal plasma cells <10 % and low level of plasma cell infiltration in a trephine biopsy (if done)
    • No related organ or tissue impairment ((no end organ damage including bone lesions)

  • Asymptomatic myeloma
    • M-protein in serum >30 g/l and/or Bone marrow clonal plasma cells >10 %
    • No related organ or tissue impairment (no end organ damage including bone lesions) or symptoms

  • Symptomatic myeloma
    • M-protein in serum and/or urine
    • Bone marrow (clonal) plasma cells or biopsy proven plasmacytoma
    • Myeloma-related organ or tissue impairment (including bone lesions)

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.